Specialty medical injectable drug program, requirements and drug policy updates

New specialty medical injectable updates and requirements announced Aug. 2023.

Aug. 23, 2023

Review the following table to determine changes to our specialty medical injectable drug programs.

SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH

Drug Name UnitedHealthcare Commercial Treatment Uses

Rystiggo®
(rozanolixizumab-noli)

 

 X Used for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.

For questions, please contact your broker or UnitedHealthcare representative.

More articles

Broker - Page template - More news Experience Fragment

Current broker or employer group client?

Access uhceservices to check commissions, manage eligibility, request ID cards and more.

Sign in